Actinogen Medical Ltd (ASX:ACW)

**Company Description:**

Actinogen Medical is an Australian biotechnology company focused on the treatment of Alzheimer’s disease and prodromal Alzheimer’s/Mild Cognitive Impairment, a transitional stage of cognitive impairment between normal aging and the more serious condition of Alzheimer’s dementia. Actinogens lead research candidate is Xanamem and its novel mechanism of action sets it apart from existing Alzheimer’s treatments. It works by blocking the production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer’s disease. There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer’s disease.

**Recent Developments:**

Significant recent developments for Actinogen include:

- The appointment of 3 global Alzheimer’s experts to the Xanamem Clinical Advisory Board and the drafting of the Phase II protocol outline for an efficacy and safety trial of Xanamem in Alzheimer’s disease. This Phase II trial is set to start in early 2016
- Excellent progress on the final Phase I clinical trial of Xanamem with recent dosage escalation approval
- A patent approval that extends Xanamem cover to 2031

**Intellectual Property/Products/Product Development Programs:**

- Xanamem is patent protected to 2031
- Xanamem’s novel mechanism of action offers a whole platform of potential additional development. Studies are being planned in further indications including PTSD, diabetes, post-myocardial infarction

**Presentation by:**

Dr Bill Ketelbey
Managing Director & CEO

Dr Bill Ketelbey is a highly experienced and successful healthcare and pharmaceutical sector professional, with 30 years' experience in the industry, including most recently in senior medical and management roles with global pharmaceutical giant, Pfizer. Prior to joining Actinogen Medical, Dr Ketelbey was Regional Vice President of Medical Affairs for Pfizer's Primary Care Business Unit for Australia and New Zealand, Japan, Canada, Korea and Country Medical Director for Pfizer Australia and New Zealand.

Dr Ketelbey has a solid track record of product development over his years in the industry leading to the successful registration, launch and commercialisation of numerous market leading medicines in a broad range of therapeutic areas, including in Alzheimer’s Disease. At Pfizer, Dr Ketelbey led the Australian/New Zealand clinical development, and was involved in the launch and commercialisation of Aricept™ (donepezil), an acetylcholinesterase inhibitor, the market leading Alzheimer’s disease therapy...
locally and globally. More recently he was involved in developing monoclonal antibodies directed at amyloid plaques, a hallmark of Alzheimer’s.

Dr Ketelbey is a medical graduate from the University of the Witwatersrand, South Africa, a Fellow of the Faculty of Pharmaceutical Physicians from the Royal College of Physicians in the UK, has an MBA from Macquarie Graduate School of Management, Australia and is a Graduate of the Australian Institute of Company Directors.

Contact Details:

Correspondence Address: Level 10, 15-17 Young Street, Sydney, NSW, 2000, Australia
Phone Number: +61 2 8964 7401
Email Address: bill.ketelbey@actinogen.com.au
Website: www.actinogen.com.au

This profile is provided by the presenting company; ASX takes no responsibility for the information included.
Participation in this event should not be taken as an endorsement by ASX of the company.